Drug Development for Multidrug-Resistant Bacteria: Why Compromise?

Mical Paul; Leonard Leibovici

doi:10.1093/infdis/jix536

Drug Development for Multidrug-Resistant Bacteria: Why Compromise?

Mical Paul^*, Leonard Leibovici

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	508-509
Number of pages	2
Journal	Journal of Infectious Diseases
Volume	217
Issue number	3
DOIs	https://doi.org/10.1093/infdis/jix536
State	Published - 17 Jan 2018

Access to Document

10.1093/infdis/jix536

Cite this

@article{233c5d4a727243dfbe05c4a834b57eb8,

title = "Drug Development for Multidrug-Resistant Bacteria: Why Compromise?",

author = "Mical Paul and Leonard Leibovici",

year = "2018",

month = jan,

day = "17",

doi = "10.1093/infdis/jix536",

language = "אנגלית",

volume = "217",

pages = "508--509",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Drug Development for Multidrug-Resistant Bacteria

T2 - Why Compromise?

AU - Paul, Mical

AU - Leibovici, Leonard

PY - 2018/1/17

Y1 - 2018/1/17

UR - http://www.scopus.com/inward/record.url?scp=85041178171&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix536

DO - 10.1093/infdis/jix536

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 29240890

AN - SCOPUS:85041178171

SN - 0022-1899

VL - 217

SP - 508

EP - 509

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -

Drug Development for Multidrug-Resistant Bacteria: Why Compromise?

Access to Document

Other files and links

Cite this